$VRTX

Reshma Kewalramani

Vertex Pharmaceuticals

President & CEO • Since 2020 • Health Care

Also profiled in: S&P 500

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

97/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: −$790M → $3.2B (+504.1% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): −$536M → $4.0B (+838.1% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Nasdaq-100 reputation leaderboard

Overview

Reshma Kewalramani is the president & ceo of Vertex Pharmaceuticals since 2020. Vertex Pharmaceuticals is a Health Care company, and one of the 100 companies in the Nasdaq-100 — every one of which is profiled on this site.

Leadership

Reshma holds the chief executive role at Vertex Pharmaceuticals with the title President & CEO — in post since 2020. This page is the concise leadership record for Vertex Pharmaceuticals in the Nasdaq-100 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $VRTX
CEO since: 2020
Index: Nasdaq-100 (#96 of 100)